Analysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) PT at $38.75

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $35.25.

A number of equities analysts have weighed in on BCYC shares. HC Wainwright decreased their price target on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a report on Monday. B. Riley reduced their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Finally, JMP Securities lowered their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, Director Bros. Advisors Lp Baker acquired 985,397 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the transaction, the director now directly owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. This represents a 11.52 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,840 shares of company stock valued at $259,128. 8.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

A number of large investors have recently modified their holdings of the company. Assetmark Inc. acquired a new position in Bicycle Therapeutics during the 3rd quarter valued at about $34,000. GAMMA Investing LLC raised its stake in shares of Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after buying an additional 1,038 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after buying an additional 2,918 shares during the period. XTX Topco Ltd bought a new position in Bicycle Therapeutics during the second quarter valued at about $206,000. Finally, Crossmark Global Holdings Inc. acquired a new position in Bicycle Therapeutics during the third quarter worth about $257,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $15.31 on Monday. Bicycle Therapeutics has a 1 year low of $12.17 and a 1 year high of $28.67. The company’s 50 day simple moving average is $22.45 and its 200 day simple moving average is $22.66. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -4.65 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same period in the prior year, the firm posted ($1.26) earnings per share. The business’s quarterly revenue was down 50.0% compared to the same quarter last year. Equities analysts expect that Bicycle Therapeutics will post -3.05 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.